Premium
Influence of budesonide on the response to inhaled terbutaline in children with mild asthma
Author(s) -
Fuglsang G.,
Agertoft L.,
VikreJorgensen J.,
Pedersen S.
Publication year - 1995
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/j.1399-3038.1995.tb00268.x
Subject(s) - medicine , budesonide , asthma , terbutaline , bronchodilator agents , pediatrics , bronchodilator
The aim of this study was to evaluate if continuous treatment with budesonide or salmeterol influences the bronchodilator response to terbutaline in children with asthma; 23 children, aged 7 to 16 years (mean = 11 years), with mild asthma were treated with inhaled budesonide 100 μg b.i.d. and placebo for three weeks in a randomized, double blind crossover study. These treatments were followed by treatment with inhaled salmeterol 50 μg b.i.d. for 3 weeks. On the last day of each period a cumulative dose‐response experiment with terbutaline in the doses 50, 100, 250 and 500 μg (cumulative dose 900 μg) was performed. Lung function was measured before and 20 min after each terbutaline inhalation. Baseline pulmonary functions after budesonide treatment were significantly higher than the baseline measured after the two other treatments (p < 0.05). After budesonide treatment, the dose‐response curve was shifted vertically upwards but otherwise parallel to the dose‐response curve after placebo. The increase from baseline after the first cumulative dose of terbutaline was significantly lower after salmeterol treatment than after the two other treatments (p < 0.01). Maximal lung functions after 900 μg terbutaline also differed significantly between the three dose‐response days; budesonide being significantly higher and salmeterol significantly lower than placebo (p = 0.02 and p < 0.001, respectively). It is concluded that budesonide treatment does not enhance the brochodilator response to terbutaline. Further studies are needed to assess if long‐term continuous salmeterol treatment reduces the response to terbutaline.